Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand

Table 5 Likelihood of having grouped HPV infection in HPV positive women with histologically confirmed high grade lesion at each level of age group by ethnicity

Category	Any HPV 16 positive^a			Any HPV 16 and/or 18 positive^a			Other HR HPV without HPV 16 and/or 18
	CIN 2	CIN 3	CIN 2/3	CIN 2	CIN 3	CIN 2/3	CIN 2	CIN 3	CIN 2/3
	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)	OR (95 % CI)
Non-Māori, 20–29 years	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Non-Māori, 30–39 years	0.8 (0.4–1.5)	0.5 (0.2–1.2)	0.6 (0.4–1.1)	0.8 (0.4–1.6)	0.5 (0.2–1.2)	0.6 (0.4–1.1)	1.4 (0.7–2.9)	2.1 (0.8–5.2)	1.7 (0.9–3.0)
Non-Māori, 40–69 years	0.6 (0.3–1.5)	0.2 (0.1–0.6)	0.4 (0.2–0.8)	0.5 (0.2–1.3)	0.4 (0.1–1.1)	0.4 (0.2–0.9)	2.0 (0.8–5.0)	2.2 (0.7–6.9)	2.1 (1.1–4.3)
Māori, 20–29 years	0.8 (0.4–1.7)	0.7 (0.3–1.6)	0.7 (0.4–1.3)	0.6 (0.3–1.4)	0.5 (0.2–1.2)	0.6 (0.3–1.0)	1.7 (0.8–3.7)	2.1 (0.8–5.4)	1.8 (1.0–3.4)
Māori, 30–39 years	0.9 (0.3–2.4)	0.4 (0.2–1.1)	0.7 (0.3–1.3)	1.2 (0.4–3.7)	0.6 (0.2–1.9)	0.9 (0.4–2.0)	0.9 (0.3–2.6)	1.6 (0.5–4.7)	1.1 (0.5–2.4)
Māori, 40–69 years	1.4 (0.4–4.1)	0.4 (0.1–1.9)	0.8 (0.3–2.1)	1.7 (0.5–5.9)	0.8 (0.1–4.4)	1.2 (0.5–3.3)	0.6 (0.2–2.2)	1.3 (0.2–7.1)	0.8 (0.3–2.3)
Test for interaction^b	P = 0.36	P = 0.52	P = 0.16	P = 0.09	P = 0.22	P = 0.02	P = 0.07	P = 0.27	P = 0.02

Other HR HPV types include infection with either type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68, not 16 or 18
^aRegardless of co-infection with other HPV types
^bLogistic regression including an interaction term for ethnicity and age group

ISSN: 1471-2334